US Bancorp
SPRY icon

US Bancorp’s ARS Pharmaceuticals SPRY Stock Holding History

US Bancorp’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8K Buy
1,599
+80
+5% +$688 ﹤0.01% 3369
2026
Q1 		$12.2K Buy
1,519
+44
+3% +$422 ﹤0.01% 3280
2025
Q4 		$17.2K Sell
1,475
-100
-6% -$973 ﹤0.01% 3144
2025
Q3 		$15.8K Buy
1,575
+649
+70% +$9.31K ﹤0.01% 3155
2025
Q2 		$16.2K Buy
926
+11
+1% +$159 ﹤0.01% 3250
2025
Q1 		$11.5K Sell
915
-19
-2% -$229 ﹤0.01% 3390
2024
Q4 		$9.85K Sell
934
-17,746
-95% -$249K ﹤0.01% 3419
2024
Q3 		$271K Buy
18,680
+18,525
+11,952% +$220K ﹤0.01% 1873
2024
Q2 		$1.32K Hold
155
– – ﹤0.01% 3774
2024
Q1 		$1.58K Hold
155
– – ﹤0.01% 3759
2023
Q4 		$849 Buy
+155
New +$679 ﹤0.01% 3814
2022
Q1 		– Sell
-1,843
Closed -$12K – 4192
2021
Q4 		$12K Buy
1,843
+1,597
+649% +$13K ﹤0.01% 3362
2021
Q3 		$2K Sell
246
-68
-22% -$1.68K ﹤0.01% 3918
2021
Q2 		$10K Buy
314
+266
+554% +$8.53K ﹤0.01% 3403
2021
Q1 		$2K Buy
+48
New +$2.27K ﹤0.01% 3731

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

US Bancorp's SPRY Position: Q2 2026 in Review

US Bancorp increased its ARS Pharmaceuticals (SPRY) stake by 5.3% in Q2 2026, buying an estimated $688 and bringing the position to 1,599 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3369.

US Bancorp first reported a position in SPRY in Q1 2021 and has held it in 15 quarters since. The position peaked at $271K in Q3 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • US Bancorp held 1,599 shares of ARS Pharmaceuticals worth $12.8K as of Q2 2026.
  • US Bancorp bought 80 ARS Pharmaceuticals shares in Q2 2026, an estimated $688.
  • ARS Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3369 holding.
  • US Bancorp first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 15 quarters since.
  • US Bancorp's ARS Pharmaceuticals position peaked at $271K in Q3 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.